Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Proteolysis targeting chimeric molecules (PROTACs) offer novel therapeutic strategies by inducing targeted protein degradation.
• Bromodomain proteins play critical roles in cancer gene transcription and are validated therapeutic targets.
• Multiple myeloma (MM) remains a significant hematologic malignancy with unmet therapeutic needs.

Purpose of the Study:

• To evaluate the therapeutic efficacy of ARV 825, a PROTAC targeting bromodomains, against multiple myeloma (MM) cells.
• To investigate the mechanisms of action and identify potential biomarkers for ARV 825 response in MM.
• To explore synergistic combinations of ARV 825 with other small molecule inhibitors.

Main Methods:

• In vitro proliferation assays, cell cycle analysis, and apoptosis studies using MM cell lines and patient samples.
• Western blotting and RNA sequencing to assess protein degradation and gene expression changes.
• In vivo studies using MM xenograft models in mice to evaluate tumor growth inhibition and survival.

Main Results:

• ARV 825 demonstrated potent, dose-dependent inhibition of MM cell proliferation, inducing cell cycle arrest and apoptosis.
• ARV 825 effectively degraded BRD2 and BRD4, with sensitivity correlating positively with cereblon expression.
• Combinations of ARV 825 with various targeted inhibitors showed synergistic anti-myeloma activity, and ARV 825 significantly suppressed tumor growth in vivo.

Conclusions:

• ARV 825 exhibits significant anti-myeloma activity both in vitro and in vivo, supporting its further investigation for MM treatment.
• Cereblon expression may serve as a predictive biomarker for ARV 825 therapy in MM patients.
• Combination strategies involving ARV 825 hold promise for improving treatment outcomes in multiple myeloma.